Introduction
Macrolide antibiotics concentrate to a large but variable extent in phagocytic cells, both in vitro and in vivo. In vitro, intracellular concentrations in human polymorphonuclear leucocytes (PMNs) are proportional to extracellular concentrations within the 0-20 mg/L range; this encompasses the plasma concentration range observed in humans during treatment with standard dosing regimens.
Erythromycin accumulates only to a modest extent in cells. Its plasma concentrations are low and erratic, due in part to its acid lability and to a short half-life (approximately 2 h). 1 Roxithromycin, an oxime derivative of erythromycin, 2 is more stable than erythromycin in acidic conditions, and so achieves higher and more reproducible plasma concentrations. Its elimination half-life is about six times that of erythromycin, and it achieves significant tissue concentrations. 3 Azithromycin, an azalide antibiotic, 4 ,5 is more stable than erythromycin in the presence of acids, but it has very low plasma concentrations because it is concentrated to a large extent in tissues. 1, 6 Azithromycin has a very long terminal half-life, in keeping with its unusually large volume of distribution.
A question often raised is to what extent such different pharmacokinetic behaviours may influence in-vivo cell accumulation when the drugs are used under clinical conditions. In this paper we propose a model in which macrolide intracellular concentrations in circulating PMNs in vivo can be predicted from the specific accumulation characteristics of each antibiotic and by the free (nonprotein bound) plasma concentrations. Using this model, we simulated the concentrations of erythromycin, azithromycin and roxithromycin within circulating PMNs after usual dosage regimens.
Materials and methods

Cell culture data
The data regarding intracellular accumulation of the macrolides were obtained from the in-vitro studies of Gladue et al. 7 
where C ec and C ic are the extracellular and intracellular concentrations, respectively.
The calculated values of K in and K out are shown in Table  I . The half-life of antibiotic release from the cells was calculated as t 1/2 ϭ log 2 /K out . The accumulation ratio at steady-state is given in this model by the ratio K in /K out .
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Computer-aided prediction of macrolide antibiotic concentrations in human circulating polymorphonuclear leucocytes and erythromycin. 10, 11 The free plasma fractions of the three antibiotics are shown in Figure 1 .
Dosage simulation
The following dosage regimens were simulated: (i) roxithromycin 150 mg po bd for 10 days; (ii) azithromycin 500 mg po (loading dose) followed by 250 mg po qds for 4 days; (iii) erythromycin (stearate) 500 mg po tds for 10 days.
Concentrations in PMNs were calculated by stepwise numerical integration over time of Equation 1, using the free plasma concentration profiles as the extracellular concentration. All calculations were performed using the RS/1 statistical software package (Bolt Beranek and Newman Inc., Cambridge, MA, USA). The main pharmacokinetic parameters for concentrations within PMNs and the total and free plasma concentrations are shown in Table II .
Results
Total and free plasma concentration profiles are shown in Figures 2 and 3 , respectively. Simulated concentrations of roxithromycin, azithromycin and erythromycin in PMNs are shown in Figure 4 . At extracellular concentrations matching in-vivo free plasma concentrations, predicted in-vivo concentrations of roxithromycin and azithromycin in PMNs are similar due to the compensatory effect of their pharmacokinetic properties (despite the 15-fold greater invitro accumulation ratio of azithromycin). Azithromycin has a large free fraction but low total plasma concentrations, with a very large volume of distribution, probably due to a high degree of tissue binding. Roxithromycin has a smaller free plasma fraction but higher total plasma concentrations, with less extensive tissue binding. In terms of free fraction and total plasma concentrations, erythromycin is in an intermediate position; its predicted in-vivo concentration in PMNs is approximately four times lower than those of roxithromycin and azithromycin.
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The time course of the ratio between PMN concentrations and free plasma concentrations of the three antibiotics is illustrated in Figure 5 . This figure, derived from the data in Figures 3 and 4 , demonstrates that the final values at pseudo-equilibrium (end of the profiles) were close to those described in vitro, despite the different kinetics of extracellular concentrations in vitro (constant) and in vivo (variable over time).
Discussion
The intracellular concentrations of macrolides depend both on the extracellular concentrations and on the intrinsic capacity of each molecule to accumulate in PMNs. The present simulations suggest that, in vivo, the concentrations of roxithromycin and azithromycin in PMNs are likely to be of the same order of magnitude, in spite of marked differences in their cell accumulation and pharmacokinetic characteristics.
The clinical significance of high intracellular concentrations of antibiotics is not clearly established. 12, 13 The mechanisms of accumulation of macrolides in phagocytic cells (ion trapping and binding to intracellular membranes) suggest that only a small fraction of the intraphagocytic drug is un-ionized and not bound within the cytoplasm or phagosomes, and thus directly microbiologically active. In this respect, the free antibiotic, which equilibrates between the plasma and the aqueous compartments of the body, may have a major role in determining the level of antibacterial activity. It has been proposed that azithromycin can be transported to the site of an infection by phagocytes 'loaded' with antibiotic. 7 This mechanism may be shared by other macrolides, especially roxithromycin, since the in-vitro data and the pharmacokinetic profiles in humans suggest that the in-vivo concentrations of these two macrolides in PMNs should be similar. Therefore, direct in-vivo measurements of PMN 'transfer' of roxithromycin and azithromycin may, therefore, be warranted, but it is still uncertain whether PMNs can keep the drug intracellularly while moving out of the blood to the site of infection and then fully release it in an active form.
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